Existing research on Baricitinib in the context of rheumatoid arthritis indicates favorable safety and efficacy profiles.[57, 58] Consequently, Baricitinib may, in the future, supersede Ruxolitinib as a more tolerable JAK inhibitor for CMML treatment. Additionally, previous research has focused more on the role of STAT5 phosphorylation in CMML,[59] with a notable absence of investigations into the application of STAT3 inhibitors, such as STATTIC. This evidence concerns the gene STAT3 and chronic myelomonocytic leukemia.